However, studies by Bayliss et al. [44] demonstrated that ERα re-expression does not always result in effective responses to SERM therapy, which is because certain cancer cells fail to re-express ERα upon inhibition of the growth factor pathway. This evidence concerns the gene ESR1 and cancer.